What's Happening?
A new study published in the journal Science, led by investigators at Dana-Farber Cancer Institute and 23andMe Research Institute, has identified a rare genetic mutation, EGFR T790M, that dramatically increases the risk of lung cancer. Carriers of this
mutation were found to have a 25-fold higher risk of lung cancer compared to individuals without it. Among those who have never smoked, the odds of developing lung cancer were 62 times higher for mutation carriers. The study analyzed data from over 3.3 million people and found no increased risk for 17 other cancers. Most U.S. carriers of this mutation were traced to a shared ancestry linked to British and Irish settlers in Southern Appalachia approximately 200-225 years ago, with the mutation being more common in certain parts of this region.
Why It's Important?
This discovery has profound implications for lung cancer screening and prevention strategies in the U.S. Currently, lung cancer screening is primarily based on smoking history. The findings suggest that genetic testing for the EGFR T790M mutation could identify a high-risk population, including non-smokers, who could benefit from personalized CT screening. Early detection in these individuals could lead to identifying lung cancers at their most curable stages, significantly improving survival rates. This could lead to a paradigm shift in public health recommendations and insurance coverage for genetic testing and screening, particularly for individuals with a strong family history of lung cancer or ancestral ties to Southern Appalachia. It also highlights health disparities that may exist due to genetic predispositions within specific populations.
What's Next?
Researchers recommend that individuals with a strong family history of lung cancer, multiple lung nodules or tumors, or family roots in parts of the southeastern U.S. consider consulting a genetic counselor about testing for the EGFR T790M mutation and potential lung cancer screening. Further studies are needed to confirm the benefit of such screening in this specific population and to determine if genetic testing improves mortality or other health outcomes. The analysis, while robust, had limitations due to the rarity of the mutation and the demographic representation of 23andMe participants. Future research will likely focus on refining risk estimates, expanding genetic screening programs, and developing targeted interventions for carriers of this mutation.
Beyond the Headlines
The study offers a fascinating insight into how human migration and genealogy can shape disease risk across generations. The concentration of the EGFR T790M mutation in Southern Appalachia due to a founder event and genetic bottleneck illustrates the complex interplay between genetics, history, and public health. This finding underscores the importance of considering ancestral background in genetic risk assessments, moving beyond generalized population studies. It also raises ethical considerations regarding genetic privacy, the potential for discrimination based on genetic predispositions, and the equitable access to genetic testing and advanced screening technologies across different socioeconomic groups. The discovery could also stimulate research into other rare genetic variants that contribute to common diseases, further personalizing medicine.
